Functionalized gold nanoparticles improve afatinib delivery into cancer cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Functionalized gold nanoparticles improve afatinib delivery into cancer cells
Authors
Keywords
-
Journal
Expert Opinion on Drug Delivery
Volume 13, Issue 1, Pages 133-141
Publisher
Informa Healthcare
Online
2015-09-16
DOI
10.1517/17425247.2015.1083973
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo
- (2015) Siao-Syun Guan et al. Oncotarget
- Enhancing the Efficiency of Gold Nanoparticles Treatment of Cancer by Increasing Their Rate of Endocytosis and Cell Accumulation Using Rifampicin
- (2014) Moustafa R. K. Ali et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model
- (2014) Hao-Wen Kao et al. NANOTECHNOLOGY
- Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles
- (2014) Yichun Qian et al. Scientific Reports
- Nanotechnology as a therapeutic tool to combat microbial resistance
- (2013) Robert Y. Pelgrift et al. ADVANCED DRUG DELIVERY REVIEWS
- Uptake of Engineered Gold Nanoparticles into Mammalian Cells
- (2013) Lev A. Dykman et al. CHEMICAL REVIEWS
- Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells
- (2013) Sílvia Castro Coelho et al. Expert Opinion on Drug Delivery
- Enhancing Proteasome-Inhibitor Effect by Functionalized Gold Nanoparticles
- (2013) Sílvia Castro Coelho et al. Journal of Biomedical Nanotechnology
- Clinical perspective of afatinib in non-small cell lung cancer
- (2013) Xiaofeng Chen et al. LUNG CANCER
- Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection
- (2012) Zeyu Xiao et al. ACS Nano
- Gold nanoparticles as novel agents for cancer therapy
- (2012) S Jain et al. BRITISH JOURNAL OF RADIOLOGY
- Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma
- (2012) Yu-Chieh Tsai et al. EUROPEAN JOURNAL OF CANCER
- Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
- (2012) A. H. Awada et al. INVESTIGATIONAL NEW DRUGS
- Quantitative Determination of Competitive Molecular Adsorption on Gold Nanoparticles Using Attenuated Total Reflectance–Fourier Transform Infrared Spectroscopy
- (2012) De-Hao Tsai et al. LANGMUIR
- Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin
- (2012) Joan Comenge et al. PLoS One
- Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
- (2011) N Ioannou et al. BRITISH JOURNAL OF CANCER
- Preparation of Peptide-Functionalized Gold Nanoparticles Using One Pot EDC/Sulfo-NHS Coupling
- (2011) Dorota Bartczak et al. LANGMUIR
- Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population
- (2011) Jong Ah Kim et al. Nature Nanotechnology
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More